Human IGFBP‑4 Biotinylated Antibody (Catalog #
Recombinant Human IGFBP-4 Protein, CF (Catalog #
Measured by its ability to neutralize IGFBP‑4 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 20‑80 µg/mL in the presence of 0.3 µg/mL Recombinant Human IGFBP‑4 and 14 ng/mL Recombinant Human IGF‑II.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
IGFBP‑4 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑4 Antibody.
Recombinant Human IGFBP‑4 (Catalog # 804-GB) inhibits Recombinant Human IGF‑II (Catalog # 292-G2) induced proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF‑II (14 ng/mL) activity elicited by Recombinant Human IGFBP‑4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP‑4 Monoclonal Antibody (Catalog # MAB8041). The ND50 is typically 20‑80 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) residue precursor protein with a predicted 21 aa residue signal peptide that is processed to generate the 237 aa residue mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% amino acid sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, 4, -5, -6), and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.
Jones, J.I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.
Insulin-like Growth Factor Binding Protein 4
Entrez Gene IDs:
3487 (Human); 16010 (Mouse)
BP-4; HT29-IGFBP; IBP4insulin-like growth factor-binding protein 4; IGF-binding protein 4; IGFBP4; IGFBP-4; IGFBP-4IBP-4; insulin-like growth factor binding protein 4
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.